Effect of Guanxin Danshen Dripping Pills on Coronary Heart Disease Comorbid with Depression or Anxiety: The ADECODE-Real World Study  

作　　者：WU Shi-hao SHI Wei-qi LI Yu-hang LIU Ru-hui HU Da-yi ZHENG Li-qiang MA Wen-lin 

机构地区：[1]Department of Geriatric Medicine,Tongji Hospital,School of Medicine,Tongji University,Shanghai 200065,China [2]Department of Cardiology,Tongji Hospital,School of Medicine,Tongji University,Shanghai 200065,China [3]Department of Cardiology,Peking University People's Hospital,Beijing 100044,China [4]School of Public Health,Shanghai Jiao Tong University,Shanghai 200030,China

出　　处：《Chinese Journal of Integrative Medicine》2024年第5期443-448,共6页中国结合医学杂志（英文版）

基　　金：Supported by the National Administration of Traditional Chinese Medicine (No.2016ZX04)。

摘　　要：Objective: To evaluate the efficacy of Guanxin Danshen Dripping Pill(GXDSDP) in treating anxiety and depression in patients with coronary heart disease(CHD). Methods: A total of 1,428 patients diagnosed with CHD screened for anxiety, depression, and quality of life(QOL) at baseline received 0.4 g of GXDSDP treatment 3 times per day and returned for monthly reassessment. Patients were recruited after stable treatment for CHD and received assessment of General Anxiety Disorder-7(GAD-7), Patient Health Questionnaire-9(PHQ-9), and Seattle Angina Questionnaire(SAQ) for evaluating anxiety, depression, and QOL.Patients were followed up 3 times, once every 4 weeks, during outpatient visits for 12 weeks. Results: At the third follow-up(F3), the anxiety symptom of 63.79%(673/1,055) of the patients improved to sub-clinical level, and the GAD-7 score improved significantly(8.11 vs. 3.87, P<0.01);57.52%(585/1,017) patients' depressive symptoms improved to sub-clinical level, with a significant improvement in PHQ-9 score(8.69 vs. 4.41, P<0.01) at F3. All aspects of QOL significantly improved at the end of treatment compared to those at baseline(all P<0.01) as assessed by SAQ: physical limitation(31.17 vs. 34.14), anginal stability(2.74 vs. 4.14), anginal frequency(8.16vs. 9.10), treatment satisfaction(13.43 vs. 16.29), and disease perception(8.69 vs. 11.02). Conclusions: A fixed dosage of GXDSDP may be a potential treatment option for CHD patients comorbid with anxiety or depression.(Registration No. ChiCTR2100051523)

关 键 词：Guanxin Danshen Dripping Pill coronary heart disease DEPRESSION ANXIETY quality of life Chinese medicine 

分 类 号：R541.4[医药卫生—心血管疾病]